

Ependion - Welcome recovery in Q4

Redeye is encouraged by the healthy rebound in demand witnessed in Ependion's Q4 report. Order bookings were 20% higher Y/Y and the improvement covered all focus segments. This marks a clear contrast to the muted market sentiment through most of 2024. Also, Westermo's EBIT margins reached new highs of almost 18%, which obviously is reassuring. The outlook is now a bit more optimistic causing us to raise our financial forecasts and valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ependion - Welcome recovery in Q4